NCT00758862View on ClinicalTrials.gov

The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions
Secondarily Infected Traumatic Lesions (SITL)Impetigo
Interventions
DRUG

2% TD1414 Cream

Application 3 times daily for 7 days

Trial Locations (1)

77840

J&S Studies, Inc., College Station

Sponsors

Lead Sponsor

LEO Pharma
All Listed Sponsors
lead

LEO Pharma

INDUSTRY

NCT00758862 - The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo | Biotech Hunter | Biotech Hunter